Supplementary Data from Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells

Xingyu Wu,Huwate Yeerna,Yusuke Goto,Toshinori Ando,Victoria H. Wu,Xuefeng Zhang,Zhiyong Wang,Panomwat Amornphimoltham,Anne N. Murphy,Pablo Tamayo,Qianming Chen,Scott M. Lippman,J. Silvio Gutkind

DOI: https://doi.org/10.1158/0008-5472.22422408.v1

2023-01-01

Abstract:supplementary methods and figure legends

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yi Huang,Jinhui Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.22470438.v1

2023-01-01

Abstract:Supplementary Figure S1. The effect of metformin on the expression of KI67, AR and neuroendocrine markers (Syn and CD56). Prostate tissues from TRAMP mice in both Control (Con) and Metformin (MET) groups at week 12, 25 and 37 were stained for KI67 (A, Magnifications: 40Ã-), AR (B, Magnifications: 20Ã-) as well as Syn and CD56 (C, Magnifications: 4Ã- for the images and 40Ã- at the lower right corner). * p < 0.05.
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

McKenzie Crist,Benyamin Yaniv,Sarah Palackdharry,Maria A Lehn,Mario Medvedovic,Timothy Stone,Shuchi Gulati,Vidhya Karivedu,Michael Borchers,Bethany Fuhrman,Audrey Crago,Joseph Curry,Ubaldo Martinez-Outschoorn,Vinita Takiar,Trisha M Wise-Draper

DOI: https://doi.org/10.1136/jitc-2022-005632

Abstract:Background: Metformin slows tumor growth and progression in vitro, and in combination with chemoradiotherapy, resulted in high overall survival in patients with head and neck cancer squamous cell carcinoma (HNSCC) in our phase 1 clinical trial (NCT02325401). Metformin is also postulated to activate an antitumor immune response. Here, we investigate immunologic effects of metformin on natural killer (NK) and natural killer T cells, including results from two phase I open-label studies in patients with HNSCC treated with metformin (NCT02325401, NCT02083692). Methods: Peripheral blood was collected before and after metformin treatment or from newly diagnosed patients with HNSCC. Peripheral immune cell phenotypes were evaluated using flow cytometry, cytokine expression by ELISA and/or IsoLight, and NK cell-mediated cytotoxicity was determined with a flow-based NK cell cytotoxicity assay (NKCA). Patient tumor immune infiltration before and after metformin treatment was analyzed with immunofluorescence. NK cells were treated with either vehicle or metformin and analyzed by RNA sequencing (RNA-seq). NK cells were then treated with inhibitors of significant pathways determined by RNA-seq and analyzed by NKCA, ELISA, and western blot analyses. Results: Increased peripheral NK cell activated populations were observed in patients treated with metformin. NK cell tumor infiltration was enhanced in patients with HNSCC treated with metformin preoperatively. Metformin increased antitumorigenic cytokines ex vivo, including significant increases in perforin. Metformin increased HNSCC NK cell cytotoxicity and inhibited the CXCL1 pathway while stimulating the STAT1 pathway within HNSCC NK cells. Exogenous CXCL1 prevented metformin-enhanced NK cell-mediated cytotoxicity. Metformin-mediated NK cell cytotoxicity was found to be AMP-activated protein kinase independent, but dependent on both mechanistic target of rapamycin and pSTAT1. Conclusions: Our data identifies a new role for metformin-mediated immune antitumorigenic function through NK cell-mediated cytotoxicity and downregulation of CXCL1 in HNSCC. These findings will inform future immunomodulating therapies in HNSCC.
Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422753

2023-01-01

Abstract:Supplementary Methods for Xie et al, MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yiqiang Huang,Jian Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.22470435

2023-01-01

Abstract:Supplementary Figure S2. The effects of metformin on prostate stroma cells. (A) The ratio of epithelial cells to stroma cells in the mice at week 12, 25 and 37. (B) WPMY-1 cells were seeded in 96-well plates with 0.5Ã-105 cells per well in growth media with or without metformin (20mM). Cell viabilities were estimated by CCK8 every other day. (C and D) WPMY-1 cells were treated with different concentrations of metformin and the numbers of cells at different stages of the cycle were analyzed by ï¬,ow cytometry (C), or stained with PI and FITC-labelled Annexin V and subsequently underwent ï¬,ow cytometry analysis to determine the percentage of apoptotic cells (D).
Supplementary Methods and References from Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

Shuyang Sun,Suling Liu,Sheng Zhong Duan,Lei Zhang,Henghua Zhou,Yongjie Hu,Xianghui Zhou,Chaoji Shi,Rong Zhou,Zhiyuan Zhang

DOI: https://doi.org/10.1158/0008-5472.22403975

2023-01-01

Abstract:Supplementary Methods and References. Description of additional methods and procedures used in the study. Also includes Supplementary References.
In Vitro and in Vivo Anti-Tumor Effect of Metformin As a Novel Therapeutic Agent in Human Oral Squamous Cell Carcinoma.

Qingqiong Luo,Dan Hu,Shuiqing Hu,Ming Yan,Zujun Sun,Fuxiang Chen

DOI: https://doi.org/10.1186/1471-2407-12-517

IF: 4.638

2012-01-01

BMC Cancer

Abstract:BACKGROUND:Metformin, which is widely used as an antidiabetic agent, has recently been reported to reduce cancer risk and improve prognosis in certain malignancies. However, the specific mechanisms underlying the effect of metformin on the development and progression of several cancers including oral squamous cell carcinoma (OSCC) remain unclear. In the present study, we investigated the effects of metformin on OSCC cells in vitro and in vivo.METHODS:OSCC cells treated with or without metformin were counted using a hemocytometer. The clonogenic ability of OSCC cells after metformin treatment was determined by colony formation assay. Cell cycle progression and apoptosis were assessed by flow cytometry, and the activation of related signaling pathways was examined by immunoblotting. The in vivo anti-tumor effect of metformin was examined using a xenograft mouse model. Immunohistochemistry and TUNEL staining were used to determine the expression of cyclin D1 and the presence of apoptotic cells in tumors from mice treated with or without metformin.RESULTS:Metformin inhibited proliferation in the OSCC cell lines CAL27, WSU-HN6 and SCC25 in a time- and dose-dependent manner, and significantly reduced the colony formation of OSCC cells in vitro. Metformin induced an apparent cell cycle arrest at the G0/G1 phase, which was accompanied by an obvious activation of the AMP kinase pathway and a strongly decreased activation of mammalian target of rapamycin and S6 kinase. Metformin treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells. In addition, metformin induced apoptosis in OSCC cells, significantly down-regulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulating the pro-apoptotic protein Bax. Metformin also markedly reduced the expression of cyclin D1 and increased the numbers of apoptotic cells in vivo, thus inhibiting the growth of OSCC xenografts.CONCLUSIONS:Our data suggested that metformin could be a potential candidate for the development of new treatment strategies for human OSCC.
Bioinformatic Analysis of Transcriptome Changes Underlying Metformin-induced Reversal of Drug Resistance in Head and Neck Squamous Cell Carcinoma Cells

shanchun hou,Qi Li,Wulong Jin,You Peng,Sujuan Niu,Xuebing Zhang,Yijie Bai,Xiaohui Xu,Jianming Hou,La Na,Zhehui Bi,Shuo Geng,Peng Xu,Feng Jun

DOI: https://doi.org/10.21203/rs.3.rs-880051/v1

2021-09-20

Abstract:Abstract Background: Metformin is the first-line drug for type II diabetes, and recent studies indicate that metformin plays an inhibitory role in multiple cancers. Metformin can also enhance the effect of chemotherapy. Although head and neck squamous cell carcinoma cells are sensitive to metformin, the mechanisms related to the metformin response and the chemosensitization effect have not been fully studied. Results: In this study, we aimed to elucidate the molecular mechanisms of metformin in HNSCC by transcriptome analysis and to reveal the underlying mechanisms of the sensitizing effects of metformin by combined online dataset analysis. mRNA sequencing and functional analysis of HNSCC samples after metformin treatment and functional analysis of mRNAs with opposite metformin-induced effects in chemosensitive versus chemoresistant cells revealed the molecular pathways, mainly the base excision repair pathway, by which this small molecule drug sensitizes HNSCC cells to treatment. Conclusions: These findings indicate that metformin exerts a hypersensitization effect by regulating the BER pathway in tumour cells, reducing their self-repair capacity after chemotherapy-induced DNA damage. In addition, the genes identified by transcriptome analysis are candidates for further investigation into the effector targets of metformin in the inhibition of HNSCC and could be applied to improve the treatment in HNSCC patients who develop resistance after advanced chemotherapy.
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Joseph Curry,Jennifer Johnson,Patrick Tassone,Marina Domingo Vidal,Diana Whitaker Menezes,John Sprandio,Mehri Mollaee,Paolo Cotzia,Ruth Birbe,Zhao Lin,Kurren Gill,Elizabeth Duddy,Tingting Zhan,Benjamin Leiby,Michelle Reyzer,David Cognetti,Adam Luginbuhl,Madalina Tuluc,Ubaldo Martinez-Outschoorn

DOI: https://doi.org/10.1002/lary.26489

Abstract:Objective: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. Study design: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full-treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. Methods: Immunohistochemistry (IHC) for the metabolic markers caveolin-1 (CAV1), B-galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki-67 IHC, were performed in pre- and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. Results: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4-fold postmetformin (P < 0.05), as measured by MSI. Conclusion: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. Level of evidence: 4. Laryngoscope, 127:1808-1815, 2017.
Transcriptional and H3K27ac related genome profiles in oral squamous cell carcinoma cells treated with metformin

Shan Liu,Congyu Shi,Xiaoru Hou,Xudong Tian,Chunjie Li,Xiangrui Ma,Xiaoyi Wang,Pan Gao

DOI: https://doi.org/10.7150/jca.63234

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:Objectives: Metformin, a first-line drug that has been used for type 2 diabetes treatment, recently attracts broad attention for its therapeutic effects on diverse human cancers. However, its effect and the underlying mechanisms on oral squamous cell carcinoma (OSCC) are not well known. Materials and Methods: OSCC cells were used to evaluate the effect of metformin on cell proliferation and colony formation in vitro. Tumor formation assay in nude mice was conducted to assess the effect of metformin in vivo. Western blotting and immunohistochemistry stain were performed to investigate the effect of metformin on the expression of acetylation at lysine 27 of histone H3 (H3K27ac) and methylation at lysine 27 of histone H3 (H3K27me3) in vitro and in vivo. RNA-seq and ChIP-seq were performed to explore the genome profile to metformin treatment in OSCC cells. Results: Metformin inhibited OSCC cell proliferation and colony formation in vitro, as well as OSCC growth in vivo. Metformin increased the global H3K27ac modification in vitro. Transcriptome analysis suggested that metformin mainly downregulated pluripotency stem cell pathway, development involved pathways and upregulated cytokine and inflammatory pathways. Additionally, H3K27ac was involved in transcription, DNA repair and replication in metformin-treated OSCC cells. Conclusions: Metformin inhibits OSCC growth concomitant upregulated global level of H3K27ac in vitro. This study provides insights into the molecule and epigenome basis on application of metformin in OSCC treatment, and highlights the underlying mechanisms of reprogrammed cancer regulation and epigenetic histone modification.

oncology
Metformin Sensitizes The Response Of Oral Squamous Cell Carcinoma To Cisplatin Treatment Through Inhibition Of Nf-Kappa B/Hif-1 Alpha Signal Axis (Vol 6, 35788, 2016)

Xiaofeng Qi,Wenguang Xu,Junqi Xie,Yufeng Wang,Shengwei Han,Zheng Wei,Yanhong Ni,Yingchun Dong,Wei Han

DOI: https://doi.org/10.1038/srep42934

IF: 4.6

2017-01-01

Scientific Reports

Abstract:A Nature Research Journal
Supplementary Tables 1-2 and Supplementary Figures S1-S5 and Legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas Via Regulating STAT3 Signaling and the Mir-21/Β-catenin Axis with HJC0152

Yu Wang,Sinan Wang,Yi‐Long Wu,Rong Yu,Zhaoqing Li,Xiaofeng Yao,Chao Zhang,Na Ye,Chao Jing,Jiabin Dong,Kailiang Zhang,Shuangqing Sun,Ming‐Hui Zhao,Wei Guo,Xin-Ping Qu,Yu Qiao,Haiying Chen,Lingping Kong,Rui Jin,Xudong Wang,Lun Zhang,Zhenhong Jia,Qiang Shen,Xuan Zhou

DOI: https://doi.org/10.1158/1535-7163.22507822.v1

2023-01-01

Abstract:Supplementary Table 1. List of primers and oligos used in this investigation; Supplementary Table 2 Primary antibodies used in this investigation; Supplementary Figure S1. HJC0152 exerts antitumor effect against HNSCC cell lines via regulating STAT3; Supplementary Figure S2. HJC0152 blocks nuclear translocation of p-STAT3 and β-catenin; Supplementary Figure S3. HJC0152 suppresses invasion and migration in HNSCC cell lines; Supplementary Figure S4. HJC0152 regulates the activity of miR-21/β-catenin axis; Supplementary Figure S5. VHL abrogation dramatically counteracts the impact of HJC0152 in vitro.
Supplementary Data from Suppression of Anoikis by skp2 Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma

Xiao-Chun Wang,Yu-Peng Wu,Bo Ye,De-Chen Lin,Yan-Bin Feng,Zi-Qiang Zhang,Xin Xu,Ya-Ling Han,Yan Cai,Jin-Tang Dong,Qi-Min Zhan,Min Wu,Ming-Rong Wang

DOI: https://doi.org/10.1158/1541-7786.22518823

2023-01-01

Abstract:Supplementary Data from Suppression of Anoikis by SKP2 Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma
Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Kankan Cao,Guodong Zhang,Moran Yang,Yiying Wang,Mengdi He,Chen Zhang,Yan Huang,Jiaqi Lu,Haiou Liu

DOI: https://doi.org/10.1158/0008-5472.23627639.v1

2023-01-01

Abstract:Materials and Methods: Supplementary Figure S1 to S14 for multiple supplementary figures
Inhibition of Autophagy Promotes the Anti-Tumor Effect of Metformin in Oral Squamous Cell Carcinoma

Wei Zhao,Chen Chen,Jianjun Zhou,Xiaoqing Chen,Kuan Cai,Miaomiao Shen,Xuan Chen,Lei Jiang,Guodong Wang

DOI: https://doi.org/10.3390/cancers14174185

2022-08-30

Cancers

Abstract:Oral Squamous Cell Carcinoma (OSCC) is the most common malignant tumor in the head and neck. Due to its high malignancy and easy recurrence, the five-year survival rate is only 50–60%. Currently, commonly used chemotherapy drugs for OSCC include cisplatin, paclitaxel, and fluorouracil, which are highly cytotoxic and cause drug resistance in patients. Therefore, a safe and effective treatment strategy for OSCC is urgent. To address this issue, our study investigated the anti-tumor activity of metformin (the first-line diabetes drug) in OSCC. We found that metformin could inhibit OSCC cell proliferation by promoting apoptosis and blocking the cell cycle in G1 phase. Additionally, we also found that metformin could induce protective autophagy of OSCC cells. After inhibiting autophagy with hydroxychloroquine (HCQ), the metformin-induced apoptosis was enhanced. In vitro, metformin inhibited the growth of subcutaneous xenograft tumor in nude mice and HCQ enhanced this effect of metformin. Therefore, metformin combined with HCQ may become a safe and effective treatment strategy for OSCC.

oncology
Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Cuicui Liu,Jiankun Qiang,Qiaodan Deng,Jie Xia,Lu Deng,Lei Zhou,Dong Wang,Xueyan He,Ying Liu,Botao Zhao,Jinhui Lv,Zuoren Yu,Qun-Ying Lei,Zhi-Ming Shao,Xiao-Yong Zhang,Lixing Zhang,Suling Liu

DOI: https://doi.org/10.1158/0008-5472.22429821.v1

2023-01-01

Abstract:Supplementary Methods, Figures and Figure legends
Supplementary Tables S1-S8 from Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

Shuyang Sun,Suling Liu,Sheng Zhong Duan,Lei Zhang,Henghua Zhou,Yongjie Hu,Xianghui Zhou,Chaoji Shi,Rong Zhou,Zhiyuan Zhang

DOI: https://doi.org/10.1158/0008-5472.22403972

2023-01-01

Abstract:Supplementary Tables S1-S8. Clinical and pathologic characteristics of SCCHN patients ; Tumorigenicity of sorted primary SCCHN cells using c-Met and CD44 markers ; The effects of c-Met knockdown on the tumor-initiating capacity of HN-CSCs ; The secondary tumor-initiating ability of cells obtained from the xenografts treated with the indicated agents ; The tumor-initiating capacity of HN-CSCs with Axin or DKK-1 overexpression ; Tumor-initiating ability of HN-CSCs with different treatments ; The target sequence of shRNAs ; Primer sequences for qPCR analyses .
Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Xiaofeng Qi,Wengguang Xu,Junqi Xie,Yufeng Wang,Shengwei Han,Zheng Wei,Yanhong Ni,Yingchun Dong,Wei Han

DOI: https://doi.org/10.1038/srep35788

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Resistance towards chemotherapy is a common complication in treatment of oral cancers, which leads to treatment failure and poor outcome. In recent years, a growing body of evidence has shown that tumour hypoxia significantly contributes to chemoresistance. Metformin, a widely used oral hypoglycaemic drug, can reportedly potentiate the efficacy of chemotherapeutic drugs in various cancers; however, the underlying mechanisms are intricate and have not been fully understood. In this study, we explored the role of metformin in chemosensitivity of oral squamous cell carcinoma cells (OSCC) to cisplatin both in vitro and in vivo, and attempted to elucidate its possible underlying mechanisms. Encouragingly, we found that metformin synergistically enhanced cisplatin cytotoxicity and reversed the chemoresistance to certain extent. This mechanism could likely be related with inhibition of the NF-κB/HIF-1α signal axis and lead to the downregulation of hypoxia-regulated genes products. Therefore, metformin could serve as a chemosensitiser for cisplatin-based regimens for OSCC, thereby providing a theoretical basis for future use in the treatment of oral cancers.
Metformin Sensitizes Hypoxia-Induced Gefitinib Treatment Resistance of HNSCC Via Cell Cycle Regulation and EMT Reversal

Xiteng Yin,Zheng Wei,Chuanhui Song,Chuanchao Tang,Wenguang Xu,Yufeng Wang,Junqi Xie,Zitong Lin,Wei Han

DOI: https://doi.org/10.2147/cmar.s177473

2018-01-01

Cancer Management and Research

Abstract:OBJECTIVES:The objectives of this study were to explore the mechanisms of metformin sensitization to hypoxia-induced gefitinib treatment in resistant head and neck squamous cell carcinoma (HNSCC) and evaluate the effects of this combined treatment strategy.METHODS:The effects of gefitinib treatment on HNSCC were measured under normoxic and hypoxic conditions. The relationship between hypoxia and cell cycle and epithelial-mesenchymal transition (EMT) in tumor cells were analyzed. Palbociclib and LY294002 were used in combination with gefitinib to evaluate the effects on HNSCC cell cytotoxicity during hypoxia. Finally, metformin was used to evaluate the sensitizing effects of gefitinib treatment on HNSCC in vivo and in vitro.RESULTS:Cell viability and apoptosis assays demonstrated a significant difference in HNSCC cells treated with gefitinib between the normoxia and hypoxia groups. Hypoxia induced the expression of cyclin D1, decreased the percentage of cells in G1, and promoted the EMT of tumor cells. Both palbociclib and LY294002 enhanced gefitinib-induced cytotoxicity of HNSCC cells under hypoxic conditions. Encouragingly, metformin sensitized HNSCC to gefitinib treatment in vivo and in vitro.CONCLUSION:Hypoxia promotes G1-S cell cycle progression and EMT in HNSCC, resulting in gefitinib treatment resistance. Metformin sensitizes HNSCC to gefitinib treatment, which might serve as a novel combined treatment strategy.

Supplementary Data from Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Supplementary Methods and References from Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

In Vitro and in Vivo Anti-Tumor Effect of Metformin As a Novel Therapeutic Agent in Human Oral Squamous Cell Carcinoma.

Bioinformatic Analysis of Transcriptome Changes Underlying Metformin-induced Reversal of Drug Resistance in Head and Neck Squamous Cell Carcinoma Cells

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Transcriptional and H3K27ac related genome profiles in oral squamous cell carcinoma cells treated with metformin

Metformin Sensitizes The Response Of Oral Squamous Cell Carcinoma To Cisplatin Treatment Through Inhibition Of Nf-Kappa B/Hif-1 Alpha Signal Axis (Vol 6, 35788, 2016)

Supplementary Tables 1-2 and Supplementary Figures S1-S5 and Legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas Via Regulating STAT3 Signaling and the Mir-21/Β-catenin Axis with HJC0152

Supplementary Data from Suppression of Anoikis by &lt;i&gt;skp2&lt;/i&gt; Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Inhibition of Autophagy Promotes the Anti-Tumor Effect of Metformin in Oral Squamous Cell Carcinoma

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Tables S1-S8 from Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Metformin Sensitizes Hypoxia-Induced Gefitinib Treatment Resistance of HNSCC Via Cell Cycle Regulation and EMT Reversal

Supplementary Data from Suppression of Anoikis by <i>skp2</i> Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma